Celadon Pharmaceuticals First Half 2024 Earnings: UK£0.037 loss per share (vs UK£0.07 loss in 1H 2023)

Celadon Pharmaceuticals (LON:CEL) First Half 2024 Results

Key Financial Results

• Net loss: UK£2.39m (loss narrowed by 44% from 1H 2023).
• UK£0.037 loss per share (improved from UK£0.07 loss in 1H 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Celadon Pharmaceuticals shares are down 21% from a week ago.

Risk Analysis

It is worth noting though that we have found 5 warning signs for Celadon Pharmaceuticals (3 make us uncomfortable!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.